{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:14:36Z","timestamp":1788250476773,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"am","delay-in-days":360,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.dld.2022.08.026","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T01:40:47Z","timestamp":1662601247000},"page":"407-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-6911","authenticated-orcid":false,"given":"M.","family":"Valery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Smolenschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boil\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Malka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.dld.2022.08.026_bib0001","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: interAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.dld.2022.08.026_bib0002","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.dld.2022.08.026_bib0003","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.annonc.2021.11.017","article-title":"Selecting the right chemotherapy in first-line advanced squamous cell carcinoma of the anus","volume":"33","author":"Ducreux","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.dld.2022.08.026_bib0004","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.dld.2022.08.026_bib0005","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Anal cancer: french Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2022.08.026_bib0006","unstructured":"10-Anus-fact-sheet.pdf [Internet]. [cited 2022 Aug 7]. Available from: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/10-Anus-fact-sheet.pdf"},{"key":"10.1016\/j.dld.2022.08.026_bib0007","unstructured":"250-france-fact-sheets.pdf [Internet]. [cited 2022 Aug 7]. Available from: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/250-france-fact-sheets.pdf"},{"issue":"2","key":"10.1016\/j.dld.2022.08.026_bib0008","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.dld.2022.08.026_bib0009","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2022.08.026_bib0010","unstructured":"anal.pdf [Internet]. [cited 2022 Feb 19]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/anal.pdf"},{"issue":"3","key":"10.1016\/j.dld.2022.08.026_bib0011","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10350-006-0786-9","article-title":"Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case","volume":"50","author":"Phan","year":"2007","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"10.1016\/j.dld.2022.08.026_bib0012","first-page":"293","article-title":"Cetuximab-Based Treatment of Metastatic Anal Cancer: correlation of Response with KRAS Mutational Status","volume":"77","author":"Lukan","year":"2009","journal-title":"OCL"},{"issue":"2","key":"10.1016\/j.dld.2022.08.026_bib0013","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1159\/000341371","article-title":"Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer","volume":"5","author":"Barmettler","year":"2012","journal-title":"Case Rep Oncol"},{"issue":"3","key":"10.1016\/j.dld.2022.08.026_bib0014","first-page":"456","article-title":"Management of Two Cases of Recurrent Anal Carcinoma","volume":"6","author":"Klimant","year":"2013","journal-title":"CRO"},{"issue":"4","key":"10.1016\/j.dld.2022.08.026_bib0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000452766","article-title":"EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: a Single-Institution Experience","volume":"92","author":"Kim","year":"2017","journal-title":"Oncology"},{"issue":"11","key":"10.1016\/j.dld.2022.08.026_bib0016","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/bjc.2012.479","article-title":"EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?","volume":"107","author":"Paliga","year":"2012","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.dld.2022.08.026_bib0017","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1309\/X4UADHVN317V2XMW","article-title":"Epidermal growth factor receptor expression in anal canal carcinoma","volume":"124","author":"L\u00ea","year":"2005","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"10.1016\/j.dld.2022.08.026_bib0018","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.humpath.2009.05.010","article-title":"Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus","volume":"40","author":"Walker","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.dld.2022.08.026_bib0019","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1471-2407-10-189","article-title":"Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas","volume":"10","author":"Van Damme","year":"2010","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.dld.2022.08.026_bib0020","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.dld.2022.08.026_bib0021","first-page":"161","article-title":"Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy","volume":"3","author":"Silva","year":"2012","journal-title":"J Adv Pract Oncol"},{"issue":"5","key":"10.1016\/j.dld.2022.08.026_bib0022","first-page":"E82","article-title":"Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal","volume":"6","author":"Rogers","year":"2015","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"10.1016\/j.dld.2022.08.026_bib0023","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00705-003-0111-z","article-title":"The biochemical and biological functions of human papillomavirus type 16 E5 protein","volume":"148","author":"Tsai","year":"2003","journal-title":"Arch Virol"},{"issue":"4","key":"10.1016\/j.dld.2022.08.026_bib0024","first-page":"513","article-title":"EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer","volume":"29","author":"Martin","year":"2014","journal-title":"Histol Histopathol"},{"issue":"10","key":"10.1016\/j.dld.2022.08.026_bib0025","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.dld.2022.08.026_bib0026","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199711063371904","article-title":"Sexually transmitted infection as a cause of anal cancer","volume":"337","author":"Frisch","year":"1997","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.dld.2022.08.026_bib0027","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.dld.2022.08.026_bib0028","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822006521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822006521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:22:16Z","timestamp":1761625336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865822006521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1590865822006521"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2022.08.026","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2022.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}